MAIA Biotechnology (MAIA) Proxy filing summary

Executive summary

• Amendment and supplement filed to provide omitted information on securities authorized for issuance under equity compensation plans as of December 31, 2025.

• Proxies submitted prior to this amendment remain valid unless changed by shareholders.

Voting matters and shareholder proposals

• Shareholders are instructed to follow existing proxy submission and voting procedures for the annual meeting on May 21, 2026.

Executive compensation and say-on-pay

• Equity compensation plans have 25,964,601 securities to be issued upon exercise of outstanding options, warrants, and rights, with a weighted average exercise price of $2.05.

• 431,153 securities remain available for future issuance under equity compensation plans.